Entrada Therapeutics (TRDA) Invested Capital (2022 - 2025)
Entrada Therapeutics (TRDA) has 4 years of Invested Capital data on record, last reported at $306.1 million in Q4 2025.
- For Q4 2025, Invested Capital fell 28.59% year-over-year to $306.1 million; the TTM value through Dec 2025 reached $306.1 million, down 28.59%, while the annual FY2025 figure was $306.1 million, 28.59% down from the prior year.
- Invested Capital reached $306.1 million in Q4 2025 per TRDA's latest filing, down from $340.7 million in the prior quarter.
- Across five years, Invested Capital topped out at $429.9 million in Q2 2024 and bottomed at $206.9 million in Q2 2023.
- Average Invested Capital over 4 years is $306.2 million, with a median of $273.4 million recorded in 2022.
- Peak YoY movement for Invested Capital: surged 107.79% in 2024, then decreased 28.59% in 2025.
- A 4-year view of Invested Capital shows it stood at $212.6 million in 2022, then increased by 14.02% to $242.4 million in 2023, then skyrocketed by 76.88% to $428.7 million in 2024, then decreased by 28.59% to $306.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $306.1 million in Q4 2025, $340.7 million in Q3 2025, and $379.5 million in Q2 2025.